Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.
de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; for PORTEC Study Group.
de Boer SM, et al.
Ann Oncol. 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753.
Ann Oncol. 2018.
PMID: 29190319
Free PMC article.
Clinical Trial.